Journal of pain research
-
Journal of pain research · Jan 2019
ATHENA: A Phase 3, Open-Label Study Of The Safety And Effectiveness Of Oliceridine (TRV130), A G-Protein Selective Agonist At The µ-Opioid Receptor, In Patients With Moderate To Severe Acute Pain Requiring Parenteral Opioid Therapy.
Pain management with conventional opioids can be challenging due to dose-limiting adverse events (AEs), some of which may be related to the simultaneous activation of β-arrestin (a signaling pathway associated with opioid-related AEs) and G-protein pathways. The investigational analgesic oliceridine is a G-protein-selective agonist at the µ-opioid receptor with less recruitment of β-arrestin. The objective of this phase 3, open-label, multi-center study was to evaluate the safety and tolerability, of IV oliceridine for moderate to severe acute pain in a broad, real-world patient population, including postoperative surgical patients and non-surgical patients with painful medical conditions. ⋯ NCT02656875.
-
Journal of pain research · Jan 2019
Aggregation properties of triamcinolone acetonide injection in human serum: considerations when performing epidural steroid injections.
Morbidity has been reported as a sequelae of crystalline steroid epidural steroid injections (ESIs), and particulate steroid size, aggregation, and embolization in brain and spinal cord may be the mechanism related to these neurologic effects. ⋯ Fewer large triamcinolone aggregates were noted in the presence of serum when compared to the non-serum control groups. However, when compared to previously studied particulate steroids, it had the largest aggregates when added to serum.
-
Journal of pain research · Jan 2019
Case ReportsNear-resolution of persistent idiopathic facial pain with low-dose lumbar intrathecal ziconotide: a case report.
Persistent idiopathic facial pain (PIFP) is a poorly defined and debilitating chronic pain state with a challenging and often inadequate treatment course. This is the first case report identifying the novel use of low-dose lumbar intrathecal ziconotide to successfully treat PIFP with nearly complete resolution of pain and minimal to no side effects. ⋯ This is the first case report describing the use of a single-shot lumbar intrathecal trial of ziconotide and subsequent placement of lumbar (as opposed to thoracic) intrathecal ziconotide pump for PIFP. A single-injection intrathecal trial is a low-risk, viable option for patients with this debilitating and frustrating pain condition. Successful trials and subsequent intrathecal pump placement with ziconotide may supplant multimodal medication management and/or invasive orofacial surgical intervention for PIFP.
-
Journal of pain research · Jan 2019
Cervical plexus as anatomical target for the treatment of postoperative cervical neuropathic pain.
Objective: The incidence of chronic neuropathic pain following neck dissections is approximately 40%. Standard drug therapy in these patients include pharmacologic treatments due to the neuropathic pain (gabapentinoids, tricyclic antidepressants…). In this case, standard options were limited. ⋯ Due to its location, superficial cervical plexus is an anatomical site with the potential risk of undergoing structural alterations (fibrosis, radiotherapy-associated retraction phenomena or neuroma formation). Interventional treatments performed under ultrasound guidance allow the dynamic application of therapies such as radiofrequency ablation. PRF could potentially cause an additive effect between neuromodulation and the hydrodissection caused by the infiltration of substances within a fibrotic area.
-
Journal of pain research · Jan 2019
The comparison of the effectiveness between different doses of local methylprednisolone injection versus triamcinolone in Carpal Tunnel Syndrome: a double-blind clinical trial.
Local corticosteroid injection is one of the most prevalent methods in treating carpal tunnel syndrome (CTS). However, the most efficient substance and its appropriate dosage remain controversial. In the present double-blind randomized controlled trial, the efficacy and safety of local injection of two corticosteroids (triamcinolone and methylprednisolone) were compared at two different dosages, 20 and 40 mg. ⋯ Based on the current data, the efficacy and safety of local injection of triamcinolone and methylprednisolone at doses of 20 and 40 mg were associated with a significant improvement in pain, functional status, and strength. Although, there was no remarkable superiority, 40 mg injection, especially for triamcinolone, yielded better NCS results and functional status.